Skip to main content

Table 1 Responsibilities of BfArM and PEI regarding IVD [1–3, 7].

From: Field safety notices released by manufacturers in cases of failure of products for infection testing: analysis of cases reported to the BfArM between 2005 and 2007

Products for immune haematological testing and tissue typing:

Annex of Directive 98/79/EC

Responsibility

   Blood groups of the AB0 system1, 2

IIa

PEI

   Blood groups of the Rhesus system (C, c, D, E, e)1, 2

IIa

PEI

   Blood groups of the Kell system1, 2

IIa

PEI

   Blood groups of the Duffy and the Kidd system1, 2

IIb

PEI

   Irregular anti-erythrocyte antibodies1, 2

IIb

PEI

   Markers for HLA 3 typing, markers DR, A and B1, 2

IIb

PEI

Products for infection testing:

  

   Markers of HIV4 infection (HIV-1 and HIV-2)1, 2

IIa

PEI

   HTLV-I5 und HTLV-II1, 2

IIa

PEI

   Hepatitis B, C und D1, 2

IIa

PEI

   Congentital infection with rubella1, 2

IIb

PEI

   Congenital infection with toxoplasma1, 2

IIb

PEI

   CMV1, 2, 6

IIb

PEI

   Chlamydia1, 2

IIb

PEI

Other products:

  

   Tumor marker PSA1, 7

IIb

BfArM

   Hereditary diseases phenylketonuria and

  

   Down syndrome (trisomy 21, including software)1

IIb

BfArM

Products for self testing:

  

   Systems for measurement of blood glucose1

IIb

BfArM

  1. 1Reagents and reagent products for detection, confirmation and quantification; 2Analysers on which these tests are performed are in the responsibility of the BfArM; 3HLA: Human leukocyte antigen; 4HIV: Human immune deficiency virus; 5HTLV: Human T-cell leukaemia virus; 6CMV: Cytomegalovirus; 7PSA: Prostate specific antigen.